Global X Management Co LLC cut its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 16.1% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,921 shares of the medical equipment provider’s stock after selling 559 shares during the quarter. Global X Management Co LLC’s holdings in ABIOMED were worth $1,195,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Baillie Gifford & Co. boosted its position in shares of ABIOMED by 3.0% during the second quarter. Baillie Gifford & Co. now owns 2,106,320 shares of the medical equipment provider’s stock worth $861,591,000 after buying an additional 61,385 shares during the period. Renaissance Technologies LLC lifted its position in ABIOMED by 35.0% in the second quarter. Renaissance Technologies LLC now owns 1,551,423 shares of the medical equipment provider’s stock worth $634,610,000 after purchasing an additional 401,800 shares during the period. Winslow Capital Management LLC acquired a new stake in ABIOMED in the first quarter worth approximately $228,454,000. FMR LLC lifted its position in ABIOMED by 34.2% in the second quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock worth $282,988,000 after purchasing an additional 176,394 shares during the period. Finally, Franklin Resources Inc. lifted its position in ABIOMED by 90.4% in the first quarter. Franklin Resources Inc. now owns 625,987 shares of the medical equipment provider’s stock worth $182,158,000 after purchasing an additional 297,270 shares during the period. Institutional investors and hedge funds own 86.21% of the company’s stock.

In other news, VP Andrew J. Greenfield sold 4,440 shares of the stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $395.00, for a total transaction of $1,753,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO David M. Weber sold 19,282 shares of the stock in a transaction on Monday, July 30th. The shares were sold at an average price of $356.77, for a total value of $6,879,239.14. Following the sale, the chief operating officer now owns 167,124 shares of the company’s stock, valued at approximately $59,624,829.48. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by corporate insiders.

ABMD has been the subject of a number of research analyst reports. BidaskClub upgraded ABIOMED from a “hold” rating to a “buy” rating in a research report on Wednesday, September 5th. Zacks Investment Research downgraded ABIOMED from a “buy” rating to a “hold” rating in a research report on Tuesday, July 31st. ValuEngine downgraded ABIOMED from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 18th. Jefferies Financial Group upped their target price on ABIOMED to $460.00 and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Finally, Piper Jaffray Companies upped their target price on ABIOMED from $360.00 to $480.00 and gave the stock an “overweight” rating in a research report on Friday, June 22nd. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $374.88.

ABMD opened at $441.52 on Wednesday. The company has a market capitalization of $18.83 billion, a price-to-earnings ratio of 154.27, a PEG ratio of 4.49 and a beta of -0.07. ABIOMED, Inc. has a 1-year low of $159.77 and a 1-year high of $450.93.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, July 26th. The medical equipment provider reported $1.95 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $1.15. ABIOMED had a return on equity of 18.91% and a net margin of 25.71%. The company had revenue of $180.01 million during the quarter, compared to the consensus estimate of $173.87 million. During the same quarter in the prior year, the firm earned $0.82 EPS. The company’s quarterly revenue was up 35.9% compared to the same quarter last year. equities analysts predict that ABIOMED, Inc. will post 3.46 EPS for the current fiscal year.

ABIOMED Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.